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ABSTRACT: Sirtuins are NAD+-dependent protein deacylases that cleave off acetyl, but also 
other acyl groups from the ε-amino group of lysines in histones and other substrate proteins. 
Dysregulation of human Sirt2 (hSirt2) activity has been associated with the pathogenesis of 
cancer, inflammation, and neurodegeneration, which makes the modulation of hSirt2 activity a 
promising strategy for pharmaceutical intervention. The Sirtuin Rearranging Ligands (SirReals) 
have recently been discovered by us as highly potent and isotype-selective hSirt2 inhibitors. 
Here, we present a well-defined structure-activity relationship study, which rationalizes the 
unique features of the SirReals and probes the limits of modifications on this scaffold regarding 
inhibitor potency. Moreover, we present a crystal structure of hSirt2 in complex with an 
optimized SirReal derivative that exhibits an improved in vitro activity. Lastly, we show cellular 
hyperacetylation of the hSirt2 targeted tubulin caused by our improved lead structure. 
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INTRODUCTION: Until today, 18 different histone deacetylases (HDACs) have been 
identified and grouped into four classes, according to their homology to yeast HDACs, which 
were the first to be discovered.1 Class I, II, and IV HDACs are Zn2+-dependent, while sirtuins, 
initially described as class III HDACs or Sir2 proteins, constitute a unique class of this enzyme 
super family. Sirtuins are dependent on NAD+ as a cofactor to remove acetyl,2 but also other acyl 
groups, such as myristoyl,3 palmitoyl,4 and succinyl,5 from the ε-amino group of lysines. Beyond 
histones, a multitude of non-histone substrates has been identified in recent years, e.g. α-tubulin,6 
NFκB,7 p53,8 and BubR1.9 Apart from deacylation, sirtuins were shown to catalyze ADP-
ribosylation as well.10 By regulating the acylation or ADP-ribosylation state of their substrate 
proteins, sirtuins have been implicated to influence a wide range of cellular processes like 
ageing,11 metabolic sensing, apoptosis,12 inflammation,13 and transcription.14 Sirtuins have been 
conserved from bacteria to eukaryotes and share a catalytic domain of approximately 260 amino 
acids with a high degree of sequence similarity. While bacteria and archaebacteria possess only 
one or two sirtuins, in eukaryotes this number is higher. The human genome encodes seven 
sirtuin isotypes, which differ in their catalytic activity and their subcellular localization.15 The 
human isotype Sirtuin 2 (hSirt2) is predominantly localized in the cytoplasm, however, it has 
also been found in the nucleus. hSirt2 was shown to have a major impact on cell cycle 
regulation,6 peripheral myelination,16 autophagy,17 and immune and inflammatory response.18 A 
dysregulation of hSirt2 activity was reported to play a critical role in the pathogenesis of 
cancer,19 neurodegenerative diseases,20 type II diabetes,21 and bacterial infections.18b, 18c To 
further investigate the effects of hSirt2-dependent deacylation, and its impact on downstream 
signaling, modulators of hSirt2 activity are urgently needed. A number of hSirt2 modulators 
have been discovered thus far, and selected examples are depicted in Figure 1: the physiological 
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sirtuin inhibitor nicotinamide (1)22 and its derivatives 5-((5-benzamidonaphthalen-1-
yl)oxy)nicotinamide (2)23 and the 3′-phenethyloxy-2-anilinobenzamide analogue 3,24 the highly 
potent but unselective ELT inhibitor 31 (4),25 the highly selective 5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (5),26 AGK2 (6),27 salermide (7),28 and 
the macrocyclic peptide S2iL5 (8).29 However, isotype-selective and drug-like inhibitors of 
hSirt2 with proven cellular activity are still scarce. Recently, we discovered a novel class of 
potent and highly isotype-selective hSirt2 inhibitors.30 Due to a major rearrangement of the 
active site of hSirt2 upon ligand binding, these inhibitors were termed Sirtuin Rearranging 
Ligands (SirReals). The core of the SirReals is an acylated 2-aminothiazole scaffold, which 
connects an arylmethyl moiety with a 4,6-dimethylpyrimidine (Figure 1).  
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Figure 1. Chemical structures and inhibition data of selected hSirt2 inhibitors, including 
SirReal1 (9) and SirReal2 (10). The intramolecular hydrogen bonds are shown as dashed lines. 
By inducing a rearrangement of the active site of hSirt2, the 4,6-dimethylpyrimidine moiety is 
bound to a yet-unexploited binding pocket, which lays the foundation for the excellent isotype-
selectivity of the SirReals. Therefore, we named the newly formed binding site ‘selectivity 
pocket’. The arylmethyl moiety protrudes towards the substrate channel pushing the acyl-lysine 
out of its physiological position, and thereby enlarging the distance between substrate and 
NAD+. This efficiently blocks the acyl transfer. A preliminary structure activity relationship 
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(SAR) study has already been reported,30 revealing an additive contribution of the arylmethyl 
and the 4,6-dimethylpyrimidine moiety, and the importance of the intramolecular hydrogen bond 
for activity. Here, we systematically probe further SARs to analyze the limits of modification 
within this scaffold. 
 
RESULTS: Guided by the structural insights obtained from hSirt2-SirReal complexes,30 we 
aimed to systematically probe the limits of variation within the scaffold of the SirReals and to 
established a well-defined SAR-model. To study the effect of an alteration of the aminothiazole 
core, we initially generated a few synthetically easily accessible aminothiadiazole derivatives. 
The synthesis of these inhibitors is outlined in Scheme 1. A condensation of a carboxylic acid 
and thiosemicarbazide yielded the aminothiadiazoles 11a-e,31 which were subsequently 
chloroacetylated to obtain 12a-g.32 A reaction of the alkyl chlorides with aromatic thiols 
generated the desired aminothiadiazoles 13a-h (Table 1).  
Scheme 1. Synthesis of aminothiadiazolesa 
 
aReagents and conditions: (a) thiosemicarbazide, H2SO4, 80 - 90 °C, 7 h; (b) acetyl chloride, 
DIPEA, acetonitrile, 0 °C to rt, 2 h; (c) aromatic thiol, Na2CO3, KI, DMSO, 2 h. 
Our main focus was placed on the modifications of the arylmethyl and pyrimidine moieties, 
which were shown to be crucial for the interaction with the cofactor or ligand binding, 
respectively.30 First, we explored modifications of the arylmethyl moiety. Molecular docking 
studies, based on the hSirt2-SirReal complexes,30 indicated that substitutions at the naphthyl 
group of the parent compound 10 are beneficial for the potency of the ligands. Compound 14a 
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(Figure 2a), a chloro-substituted derivative of the parent compound 10, was predicted to interact 
with the two backbone carbonyl groups of His187 and Val233 (Figure 2b). By means of a 
halogenation of the naphthyl residue, we aimed to gain ligand affinity via a σ-hole interaction 
with the peptide backbone. To follow up on this hypothesis we synthesized the halogenated 
naphthyl derivatives 14a, 14d, 14f, 14g, 14i (Table 2). Additionally, novel derivatives of the 
parent compound 9, with substituted benzyl moieties, were generated to consider the impact of 
further structural changes of the arylmethyl moiety, as well. Encouraged by molecular docking 
studies, that showed a high docking score for the (S)-enantiomer of 14b (Figure 2a,c), we aimed 
to synthesize SirReals with an additional alkylation in α-position to the carbonyl of the amide 
and eventually separated the enantiomers by chiral HPLC. The docking revealed that the methyl 
group ((S)-configuration) is orientated towards the exit of the selectivity pocket, which can 
accommodate longer alkyl groups. On the other hand, the (R)-configuration was predicted to be 
less favorable due to the close proximity of the conserved water molecule and Ile93. This is also 
reflected in the less favorable binding energies calculated for the (R)-enantiomer (Table S1). 
Furthermore, we wanted to investigate the effects of structural changes of different substitution 
patterns of the pyrimidine moiety. Initial structural data and SAR studies have shown that the 
4,6-dimethylpyrimidine moiety perfectly fits into the newly formed ‘selectivity pocket’, and that 
a loss of the methyl groups leads to a decay in ligand potency.30 Additionally, molecular 
docking, based on hSirt2-SirReal complexes,30 demonstrated by the example of 14c (Figure 2a), 
that larger alkyl substituents, e.g. ethyl, in position 4 and 6 of the pyrimidine moiety cause a 
steric clash with residues Ala135, Tyr139, and Leu206 of the ‘selectivity pocket’, as well as with 
Thr171 of the C-pocket. These studies predicted a loss of the H-bond to the conserved water 
molecule, and thereby lowering the ligand affinity to hSirt2 (Figure 2d). To show the accuracy of 
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our docking studies we still wanted to actually test, whether hSirt2 would be able to 
accommodate its ‘selectivity pocket’ to other substitution patterns of the pyrimidine moiety, as 
well.  
 
Figure 2. Docking poses derived for the envisaged SirReals 14a-c. (a) Chemical structures used 
for docking studies. (b) Docking pose derived for 14a (colored magenta). Distances between the 
halogen atom and the two carbonyl groups of His187 and Val233 are shown as blue lines with 
distances given in Angstrom. (c) Docking pose derived for (S)-14b (colored cyan). The methyl 
group ((S)-configuration) is orientated towards the exit of the ‘selectivity pocket’ which can 
accommodate longer alkyl groups. The molecular surface of the binding pocket is displayed and 
colored according to the hydrophobicity (green=hydrophobic, magenta= hydrophilic). (d) 
Docking pose derived for 14c (colored green) in comparison with the X-ray structure of 10 
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(colored orange). The larger ethyl groups of the pyrimidine ring cause steric clashes with Ala135 
and Leu206 and, as a consequence, the H-bond to the conserved water molecules is lost. 
Hydrogen bonds are shown as dashed cyan colored lines, water molecules as red spheres.  
To establish a well-defined SAR model, we set up a synthesis platform to generate a 
2-aminothiazole library that was directed to yield compounds with a broad structural variety, 
particularly in the arylmethyl and pyrimidine parts of the ligand (Scheme 2).  
 
Scheme 2. Synthesis platform utilized to generate the 2-aminothiazole librarya 
 
aReagents and conditions: (a) NaNO2, HCl, water, -5 – 0 °C, 10 min; (b1) acrolein, CuCl2 x 2 
H2O, acetone, 3 h; (b2) NaHCO3, MgO; then acrolein, CuCl2 x 2 H2O, acetone, 3 h; (b3) FeCl3 x 
6 H2O, HCl, water, -5 – 0 °C; then CuCl2 x 2 H2O, HCl, acetone/ethanol, -5 – 0 °C; then 
acrolein, acetone/water, 4h; (c) thiourea or N-methylthiourea, ethanol, reflux, 2 h; (d) acyl 
chloride, DIPEA, acetonitrile, 0 °C to rt, 2 h; (e) aromatic thiol, Na2CO3, KI, DMSO, 2 h. 
 
The biggest challenge within the synthesis of the SirReals was the preparation of 
α-chloropropanals via Meerwein reaction,33 due to the instability of some arenediazonium salts, 
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especially the naphthalenediazonium salts.34 In order to overcome these issues, we had to use 
three different methods to obtain sufficient amounts of the appropriate α-chloropropanals.35 
Toluene- and methoxybenzenediazonium salts could only be converted into the appropriate α-
chloropropanals under standard Meerwein conditions in a neutral medium,35a while halogenated 
benzenediazonium salts, as well as the diazonium salt from 4-phenylaniline, successfully reacted 
in an acidic medium. For the synthesis of the 5-(naphthylmethyl)thiazol-2-amine derivatives 
15a-f, we followed a modified version of the Meerwein reaction published by Obushak et al.35b 
Initially, naphthalenediazonium chlorides were treated with iron(III) chloride in an aqueous 
solution to obtain the naphthalenediazonium tetrachloroferrates(III). An exchange reaction with 
CuCl2 in acetone resulted in the precipitation of the naphthalenediazonium 
tetrachlorocuprates(II), which were isolated and used as a fine crystalline powder for the 
subsequent reaction with acrolein.35b With this protocol, we were able to generate the desired 
naphthyl derivatives 15b-c, which could not be synthesized under standard Meerwein conditions, 
neither in an acidic nor in a neutral medium. For those naphthylamines that could be transformed 
into the corresponding α-chloropropanals using standard Meerwein conditions to a small 
extent,35a the modified version of the Meerwein reaction enabled us to increase the yield of this 
reaction largely. However, due to the time-consuming protocol of the modified Meerwein 
reaction, it was exclusively used to synthesize the naphthyl derivatives 15a-f and compound 16g, 
which could not be generated in satisfying yields applying standard Meerwein conditions. The 
α-chloropropanals were immediately converted into the aminothiazole scaffold (15a-f, 16a-g) by 
condensation with thiourea.35a The aminothiazoles were subsequently chloroacetylated32 to yield 
17a-j and 18a-i, followed by a nucleophilic substitution with an aromatic thiol to generate 
compounds 14a-r, 19a-q and 20a-d. The synthesis of the halogenated 1-naphthylamines (21a-c), 
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which were needed as starting materials for the synthesis of the halogenated inhibitors (14a, 14d, 
14f, 14g, 14i), is illustrated in Scheme 3 by the example of the chlorinated 1-naphthylamines 
21a-b. Starting with the nitration of 2-aminonaphthalene-1-sulfonic acid followed by a 
desulfonation36 the isomers of the respective nitronaphthalenamines 22a-b were separated by 
flash chromatography. Halonitronaphthalenes 23a-c were synthesized by applying Sandmeyer 
conditions.37 Finally, the halogenated 1-naphthylamines 21a-c were obtained by a reduction of 
the nitro group with SnCl2. 
Scheme 3. Synthesis of chlorinated 1-naphthylamines as starting material for further 
synthesesa 
  
aReagents and conditions: (a) H2SO4, KNO3, -15 °C, 40 min; (b) H2SO4/water (1:1), reflux, 40 
min; (c) glacial acid, H2SO4, NaNO2, 15-20 °C, 15 min; then CuCl and HCl, rt, 1 - 4 h; (d) SnCl2 
x 2 H2O, ethanol, rt, 4 – 24 h. 
The synthesized SirReal derivatives were evaluated for their inhibitory activity against hSirt1 
and hSirt2 in a biochemical in vitro assay that was previously described.38 The in vitro inhibition 
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data of the aminothiadiazoles (13a-h) and the aminothiazole derivatives 20a-d, 24a-b, 25, 26a-b 
and 27-32, which strongly deviate from the original scaffold is summarized in Table 1. 
Aminothiazoles (9-10, 14a-r, 19a-q) and their in vitro inhibition of hSirt1 and hSirt2 are shown 
in Table 2. 
 
Table 1. In vitro inhibition of hSirt1 and hSirt2 by aminothiadiazoles 13a-h and aminothiazoles 
20a-d, 24a-b, 25, 26a-b and 27-32 
Shared scaffold or complete 
chemical structure 
compd R1 R2 
hSirt1 inhibition 
%@conc. [µM] 
or IC50 ± SE [µM] 
hSirt2 inhibition 
%@conc. [µM] 
or IC50 ± SE [µM] 
 
13a 1-naphthylmethyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µMc 1.89 ± 1.50 
13b phenyl 5,6-diphenyl-1,2,4-triazin-3-yl n.i.@ 200 µM 19.9 ± 31.7 
13c 4-chlorobenzyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µM 30.9 ± 20.5 
13d 4-bromobenzyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µM 167.7 ± 30.29 
13e trifluoromethyl 4,6-dimethylpyrimidin-2-yl 12% @ 200 µM 502.8 ± 43.95 
13f phenyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µM 19.9% @ 50 µM 
13g benzyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µM 17.8% @ 50 µM 
13h methyl 4,6-dimethylpyrimidin-2-yl n.i.@ 200 µM n.i. @ 50 µM 
 
20a 3-hydroxyphenyl  n.i.@ 200 µM 143 ± 27.4  
20ba 
3,5-
dimethylphenyl 
 16% @ 200 µM 207 ± 27.4 
20c 2-aminophenyl  n.i.@ 200 µM 36% @ 50 µM 
20d 4-chlorophenyl  n.i.@ 200 µM n.i. @ 50 µM 
 
24a CH3  n.i.@ 200 µM 
84% @ 500 µM 
n.i. @ 50 µM 
24b C5H11  n.i.@ 200 µM 
77% @ 500 µM 
48% @50 µM 
n.i. @ 10 µM 
 
25   39% @ 200 µM 289 ± 127 
 
26a 
4,6-
dimethylpyrimidin
-2-yl 
 16% @ 200 µM 77.8 ± 7.62 
26bb 
4-hydroxy-6-
propyl-pyrimidin-
2-yl 
 n.i.@ 200 µM n.i. @ 50 µM 
 
27   28% @ 200 µM 18% @ 50 µM 
 
28   23% @ 200 µM 35% @ 50 µM 
 
29   n.i.@ 200 µM 33.0 ± 15.4 
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aCompound previously published by our group30 
bSirtuin inhibitor presented by Kazantsev et al.39 
cn.i.: inhibition @ conc. [µM] < 10% 
 
Among the aminothiadiazoles, compound 13a, bearing a 1-naphthylmethyl and a 4,6,-
dimethylpyrimidine moiety, displays the most potent hSirt2 inhibition. This is consistent with the 
previously published SirReal-mediated inhibition of hSirt2.30 However, a switch from the 
aminothiazole to the aminothiadiazole scaffold was shown to lead to a loss in potency, and was 
therefore not further investigated. Furthermore, we observed a substantial decrease in potency for 
those compounds that strongly deviate from the original scaffold (20a-d, 24a-b, 25, 26a-b and 
27-32, Table 1). Thus, we hypothesize that the unique mechanism of SirReal-mediated hSirt2 
inhibition is restricted to compounds that display a high extent of similarity to the parent 
compounds 9 or 10. By disassembling our lead structure 10 into fragments (24a, 30-32, Table 1), 
we clearly demonstrate that the presence of all three functional elements, namely: arylmethyl, 
aminothiazole, and 4,6-dimethylpyrimidine is crucial for efficient inhibition of hSirt2 activity. 
 
 
 
 
 
 
 
30   n.i.@ 200 µM 24% @ 250 µM 
 
31   n.i.@ 200 µM n.i. @ 50 µM  
 
32   n.i.@ 200 µM n.i. @ 50 µM  
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Table 2. In vitro inhibition of hSirt1 and hSirt2 by aminothiazoles 9-10, 14a-r, 19a-q 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCompounds previously published by our group30 
bn.i.: inhibition @ conc. [µM] < 10% 
 
Analyzing the data of Table 2, we can confirm the findings of our preliminary SAR model,30 
highlighting the importance of the 4,6-dimethylpyrimidine moiety for the binding of the ligand to 
 
 
 
Shared scaffold: 
 
compd Aryl R1 R2 R3 R4 R5 
hSirt1 inhibition 
%@conc. [µM] 
or IC50 ± SE [µM] 
hSirt2 inhibition 
%@conc. [µM] 
or IC50 ± SE [µM] 
9a phenyl H H CH3 H CH3 15% @ 200 µM 3.75 ± 0.83 
10a naphthalen-1-yl  H H CH3 H CH3 n.i.@ 200 µM 0.44 ± 0.08 
14a 7-chloronaphthalen-1-yl H H CH3 H CH3 29% @ 200 µM 0.18 ± 0.02 
rac-14b naphthalen-1-yl H CH3 CH3 H CH3 17% @ 200 µM 0.42 ± 0.04 
(S)-14b naphthalen-1-yl H (S)-CH3 CH3 H CH3 n.i.@ 200 µM 0.26 ± 0.03 
(R)-14b naphthalen-1-yl H (R)-CH3 CH3 H CH3 n.i.@ 200 µM 9.77± 4.78 
14c naphthalen-1-yl  H H C2H5 H C2H5 n.i.@ 200 µM 45.6 ± 24.6 
14d 7-bromonaphthalen-1-yl H H CH3 H CH3 n.i.@ 200 µM
b 0.21 ± 0.02 
14e 2-methylnaphthalen-1-yl H H CH3 H CH3 n.i.@ 200 µM 0.31 ± 0.01 
rac-14f 7-chloronaphthalen-1-yl H C2H5 CH3 H CH3 n.i.@ 200 µM 0.32 ± 0.05 
14g 6-chloronaphthalen-1-yl H H CH3 H CH3 20% @ 200 µM 0.48 ± 0.05 
rac-14h naphthalen-1-yl  H C2H5 CH3 H CH3 35% @ 200 µM 0.54 ± 0.06 
rac-14i 7-chloronaphthalen-1-yl H CH3 CH3 H CH3 n.i.@ 200 µM 0.54 ± 0.08 
14j naphthalen-1-yl  H H CH3 H H n.i.@ 200 µM 1.45± 0.18 
rac-14k naphthalen-1-yl  H CH3 H H H 21% @ 200 µM 1.92 ± 0.42 
14la naphthalen-1-yl  H H H H H 17% @ 200 µM 2.34 ± 0.42 
14m naphthalen-1-yl  H H CH3 CH3 CH3 n.i.@ 200 µM 15.0 ± 2.11 
14n naphthalen-2-yl  H H CH3 H CH3 n.i.@ 200 µM 65.0 ± 31.7 
14o naphthalen-1-yl  H H OH H C3H7 22% @ 200 µM 127.2± 13.4 
14pa naphthalen-1-yl  CH3 H CH3 H CH3 n.i.@ 200 µM >100 
14q naphthalen-1-yl  H H OH H CH3 n.i.@ 200 µM 35% @ 50 µM 
14r naphthalen-1-yl H H NH2 H NH2 n.i.@ 200 µM 25% @ 50 µM 
19a 3-ethoxyphenyl H H CH3 H CH3 n.i.@ 200 µM 1.33 ± 0.15 
19b 3-methylphenyl H H CH3 H CH3 18% @ 200 µM 1.64 ± 0.40 
19c 4-chlorophenyl H H CH3 H CH3 n.i.@ 200 µM 3.40 ± 0.49 
19d 4-methylphenyl H H CH3 H CH3 16% @ 200 µM 4.72 ± 5.55 
rac-19e 4-methoxyphenyl H CH3 CH3 H CH3 27% @ 200 µM 14.6 ± 9.24 
19fa phenyl H H H H H 12% @ 200 µM 16.8 ± 4.96 
rac-19g 4-biphenyl H CH3 CH3 H CH3 14% @ 200 µM 33.0 ± 13.8 
19h 4-biphenyl H H CH3 H CH3 29% @ 200 µM 164.5 ± 23.4 
19i 4-biphenyl H H C2H5 H C2H5 10% @ 200 µM 31% @ 50 µM 
19j 2-methylphenyl H H CH3 H CH3 14% @ 200 µM 52% @ 50 µM 
19k 4-methoxyphenyl H H CH3 H CH3 n.i.@ 200 µM 48% @ 50 µM 
19l 4-methoxyphenyl H H C2H5 H C2H5 17% @ 200 µM 48% @ 50 µM 
19m 4-chlorophenyl H H C6H5 H C6H5 11% @ 200 µM 46% @ 50 µM 
rac-19n 4-methoxyphenyl H CH3 C2H5 H C2H5 18% @ 200 µM 40% @ 50 µM 
19o 4-chlorophenyl H H C2H5 H C2H5 18% @ 200 µM 38% @ 50 µM 
19p 2-methylphenyl H H H H H 11% @ 200 µM n.i. @ 50 µM  
19q 3-methylphenyl H H C2H5 H C2H5 n.i.@ 200 µM n.i. @ 50 µM  
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the newly formed ‘selectivity pocket’. On the one hand, we show that ligands lose their affinity 
without the methyl groups at the pyrimidine ring in position 4 and/or 6 (14j-l), on the other hand 
we reveal that a higher degree of methylation (14m) or bulkier substituents (14c, 19l, 19n-o) 
cause a decrease in potency, as predicted by molecular docking studies (Figure 2d). Furthermore, 
we could show that polar substituents at the pyrimidine ring, e.g. -OH or -NH2 (14q-r), are not 
beneficial in terms of potency. The inhibition data of the novel ligands with 2-naphthyl (14n), 
biphenyl (19g-i) or substituted phenyl moieties (19a-e, 19j-q), which were generated to study the 
impact of structural changes of the arylmethyl moiety, clearly indicates the superiority of the 1-
naphthyl substituted SirReals. We were able to rationalize the observed loss of in vitro potency 
caused by replacing the 1-naphthyl moiety with other aryl substituents e.g. biphenyl, by means of 
docking studies. These indicate a steric clash with the residues Val233, Phe234 and Phe235 of 
the binding pocket (data not shown). Comparing the substituted phenyl ligands with their parent 
compound 9, we conclude that a substitution in position 3 is beneficial in terms of hSirt2 
inhibition (19a-b), whereas other substitution patterns lead to a decrease in potency (e.g. 19c-d, 
19j). This observation is reflected by the docking results (Table S1) where we propose that the 4-
position of the phenyl ring is unfavorable for substitution due to the close proximity of Phe234, 
whereas in the 3-position the substituent protrudes into the acyl-lysine channel (not shown). As 
predicted by molecular docking, an alkylation in the α-position of the amide leads to increased 
potency of the (S)-enantiomer in the case of the methyl group ((S)-14b). Compared to rac-14b, 
an ethyl group already led to a decrease in potency (rac-14h). As the ethyl compounds (rac-14h, 
rac-14f) additionally turned out to be poorly soluble, we therefore did not separate the 
enantiomers of those compounds. Most importantly, however, we improved the in vitro activity 
of our lead structure by a chlorination or bromination of the naphthyl residue in position 7 (14a, 
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14d). We were able to rationalize these results by binding free energy studies in combination 
with molecular docking (See Methods section for further details). Using docking poses 
calculated with the program GLIDE (Schrödinger LLC, New York, USA) and subsequent 
refinement using the program AMBER and a GBSA solvation model implemented in MOE 
2012.10 (Chemical Computing Group, Montreal, Canada) we observed a correlation between the 
experimental pIC50 values and the calculated binding energies EGBSA (r
2=0.67, RMSE 0.60, 
q2LOO=0.62, Figure S1). An improvement of the model was derived by including two topological 
descriptors describing the ligand structures (“diameter” and surface descriptor “PEOE_VSA4”, 
see Methods section). The resulting model showed the following equation: 
pIC50 = -1.474 – 0.192 “diameter” – 0.032 “PEOE_VSA4” – 0.195 “EGBSA” 
 “Diameter” is the largest value in the distance matrix dimension of the molecules and is an 
indicator of the dimension of the molecules. Increasing the “diameter” of the inhibitors is 
unfavorable as well as increasing the surface descriptor “PEOE_VSA4”. The final quantitative 
structure activity relationship (QSAR) model is able to rationalize the observed in vitro activities 
of the developed inhibitors (r2=0.81, RMSE 0.45, q2LOO=0.76, Figure S2). The QSAR model was 
further tested by 10-fold cross validation using randomly selected 20% of the compounds as test 
set. The calculated q2L20%O value of 0.74 supports the robustness of the model. 
Moreover, we were able to rationalize these results with a crystal structure of hSirt2 in complex 
with 14d and NAD+ (Figure 3).  
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Figure 3. 14d of the hSirt2-14d-NAD+ complex binds to hSirt2 in a similar fashion as observed 
for 10 of the hSirt2-10-NAD+ complex. (a) Superposition of the hSirt2-10-NAD+ complex 
(cartoon: slate blue, PDB-ID 4RMG) with the crystal structure of hSirt2-14d-NAD+ (cartoon: 
pale green; 14d: raspberry sticks; NAD+: pale yellow sticks). Both complexes adopt the ‘locked 
open’-conformation (RMSD of all Cα-atoms: 0.33 Å). (b) 14d and NAD+ of the hSirt2-14d-
NAD+ complex assume a very similar position within the active site of hSirt2 as 10 and NAD+ of 
the hSirt2-10-NAD+ structure. (c) 14d as well as NAD+ are well-defined by the electron density. 
σ-weighted iterative OMIT maps are shown as green mesh and contoured at 3.0σ. (d) 
Interactions of 14d with hSirt2. Interacting residues are represented as sticks (green). Phe190, 
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Ile232 are not labeled and Leu206 is not shown for the sake of clarity. The water molecule is 
represented as a black sphere and hydrogen bonds as dashes yellow lines. 
The crystal structure reveals that 14d, as well as NAD+, assume a very similar position within the 
active site of hSirt2 compared to 10 and NAD+ of the hSirt2-10-NAD+ structure (Figure 3a-b). 
We were not able to observe a σ-hole interaction in our co-crystal structure as suggested by the 
docking study. Binding of 14d is mainly driven by hydrophobic interactions with the side chains 
of the residues forming the extended C-site (ECS), the acyl-lysine binding site as well as the 
‘selectivity pocket’ at the hinge region. The 7-bromonaphthyl substituent fills the lipophilic 
naphthyl binding site more efficiently than the unsubstituted naphthyl moiety, and thereby allows 
further hydrophobic interactions. The carbonyl-O of the amide also forms a water-mediated 
hydrogen bond to the backbone carbonyl-O of Pro94. As it was already observed in the crystal 
structure of hSirt2-10-NAD+, 14d also forms an intramolecular hydrogen bond between the 
amide N-H and one of the nitrogen atoms of the dimethylpyrimidine ring. (Figure 3d). To see, 
whether the combination of beneficial substitution patterns would lead to a further increase in 
potency, we combined a 7-chloro substituent with an α-methylation in the amide part. Yet, we 
did not detect an additive effect by combining a 7-halonaphthyl moiety with a methylation in the 
α-position of the amide (rac-14i). 
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To assess the cellular activity of the 7-halonaphthyl derivatives, we utilized immunofluorescence 
microscopy and western blot experiments, showing an enhanced tubulin hyperacetylation for 
14a, when compared to DMSO control (Figure 4, for raw images see Figure S3, for western blots 
Figure S4).  
 
Figure 4. Optimized aminothiazole 14a induces tubulin hyperacetylation in cultured HeLa cells. 
Acetylation level of the microtubule network (red) in the presence or absence of sirtuin inhibitors 
(10 µM). Treatment of HeLa cells with 14a leads to higher acetylation levels of the microtubule 
network as compared to the DMSO treated cells (negative control). 10 was used as a positive 
control. Nuclei were DAPI-stained (blue). The scale bar represents 10 µm. 
Treatment with the optimized SirReal derivative 14a leads to hyperacetylation of the microtubule 
network in a similar manner as observed for 10, which was used as a positive control. While 
compounds 14a and 10 both lead to a significant increase in tubulin hyperacetylation at a 
concentration of 20 µM, 14a also induces a significant gain in tubulin acetylation at only 10 µM 
(Figure S4). Thus, we could show that the improved in vitro potency of 14a is also relevant 
under physiological conditions. Of note, the halogenated derivatives were badly soluble in cell 
culture media and may therefore be limited in their efficacy at higher concentrations. 
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DISCUSSION AND CONCLUSION: Starting out from compounds 9 and 10 as potent and 
selective hSirt2 inhibitors, we established a synthesis platform to systematically probe the limits 
of modification within this scaffold. We were able to elaborate a well-defined SAR model for 
both, the arylmethyl and the pyrimidine moiety. Guided by the structural knowledge, revealed by 
hSirt2-9/10 co-crystals as well as molecular docking studies, we were able to improve the in 
vitro hSirt2 inhibition of both lead structures, 9 and 10. Moreover, the cellular activity of the 
improved aminothiazole inhibitor 14a was validated by tubulin hyperacetylation in HeLa cells. 
In combination with the herein reported co-crystal structure, our SAR model will be the 
foundation for further developments of the Sirtuin Rearranging Ligands as valuable biological 
tool compounds to gain deeper insight into sirtuin biology and to probe the druggability of 
sirtuins. 
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EXPERIMENTAL SECTION:  
1. Protein expression and purification: hSirt1133-747 was expressed as a GST-tagged enzyme 
and purified as described previously.40 hSirt225-389 was expressed N-terminally tagged with His6
41
 
with minor modifications.40 hSirt256-356 was expressed and purified according to Rumpf et al.
30  
2. In Vitro Testing: Potency of hSirt1 and hSirt2 inhibition was determined with a fluorescence-
based homogeneous assay using the substrate ZMAL (Cbz-Lys(acetyl)-AMC).38 hSirt1133-747 or 
hSirt225-389 were mixed with assay buffer (50 mM Tris, 137 mM NaCl, 2.7 mM KCl, pH 8.0), 
NAD+ (final assay concentration 500 µM), the substrate ZMAL (final assay concentration 10,5 
µM), the inhibitor dissolved in DMSO at different concentrations, or DMSO only as a control 
(final DMSO concentration 5% (v/v)). To ensure initial state conditions, total substrate 
conversion of controls was adjusted to approximately 15% - 30%. The assay was performed in 
96-well plates with a reaction volume of 60 µL per well. All determinations were performed at 
least in duplicates. After an incubation of 4 h at 37 °C and 140 rpm, deacetylation reaction was 
stopped by the addition of 60 µL of a stop solution containing trypsin and nicotinamide (50 mM 
Tris, 100 mM NaCl, 6.7% (v/v) DMSO, trypsin 5.5 U µL-1, 8 mM nicotinamide, pH 8.0). The 
reaction mixture was further incubated for 20 min at 37 °C and 140 rpm. Fluorescence intensity 
was measured in a microplate reader (BMG Polarstar, λex = 390 nm, λem = 460 nm). Rates of 
inhibition were determined by using the controls, containing no inhibitor, as a reference. 
Graphpad Prism software (La Jolla, CA) was employed to determine IC50 values. 
3. Data collection, structure solution and refinement: Data were collected at 100 K at X06SA 
beamline of the Swiss Light Source (Villigen, Switzerland) equipped with a Pilatus 6M detector 
at a wavelength of 1.0 Å with oscillations of 0.5°. Data were processed with XDS42 and scaled 
based on the CC1/2 criterion43 using Aimless.44 Data collection statistics are shown in Table 5. 
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The structure was solved by molecular replacement with MOLREP45 using the hSirt2-10-NAD+-
complex (PDB-ID 4RMG)30 as a search model. The structural model was built in Coot46 and 
refined with REFMAC.47 14d was generated with the Grade Web Server (Global Phasing Ltd., 
United Kingdom) and placed into 2Fo-Fc electron density maps using AFITT-CL (Version 2.1.0, 
OpenEye Scientific Software, Inc., Santa Fe, NM, USA.). All residues except Pro99, Ser100 and 
Thr101 were included in the model. The N-terminal glycine, histidine and methionine originate 
from the TEV cleavage site and the NdeI-restriction site of the modified pET15b- expression 
vector. The structure was validated using the Molprobity server48 and PROCHECK.49 σ-
weighted iterative OMIT maps were generated with Phenix.50 RMSD values were determined 
with SUPERPOSE51 and images were prepared with Pymol (The Pymol Molecular Graphics 
System, Version 1.7, Schrödinger, LLC). 
Table 5. Data collection and refinement statistics 
 
 hSirt2-14d-NAD+ 
Data processing  
PDB accession # 5DY4 
Spacegroup I2 
a, b, c (Å) 84.30, 55.43, 96.18 
α, β, γ  (°) 90, 114.91, 90 
Resolution (Å) 46.78–1.77 (1.81–1.77) 
Unique observations 38622 (2201) 
Observations 260647 (15296) 
Completeness (%) 98.2 (98.1) 
Multiplicity 6.7 (6.9) 
Rmerge 
[1] 0.095 (2.050) 
I / σI 10.3 (1.0) 
CC1/2 0.998 (0.554) 
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Refinement  
Resolution (Å) 46.78–1.77 (1.81–1.77) 
No. Amino acids 300 
No. Atoms 2649 
Protein 2391 
14d 30 
NAD+ 44 
Waters 183 
Zn2+ 1 
Rcryst/Rfree (%) 
[2] 17.5/21.3 
B factors (Å2)  
Protein 33.71 
14d 27.88 
NAD+ 29.05 
Waters 38.64 
Zn2+ 27.58 
RMSD bond length (Å) 0.013 
RMSD angles (°) 1.65 
Ramachandran plot statistics  
Most favoured region (%) 93.2 
Additional allowed region (%) 6.5 
Generously allowed region (%) 0.3 
Disallowed region (%) 0.0 
Values in parentheses represent the highest resolution shell. 
[1] 
Rmerge = ∑hkl [(∑i |Ii - <I>|) / ∑iIi] 
[2] 
Rcryst = ∑hkl ||Fobs| - |Fcalc|| / ∑hkl |Fobs| 
Rfree is the cross-validation R factor computed for a test set of 5 % of unique reflections 
selected randomly.52 Ramachandran statistics as defined by PROCHECK.49 
4. Protein crystallization: Crystallization assays were set up with the Oryx Nano pipetting robot 
(Douglas Instruments, United Kingdom) using the vapor diffusion sitting drop method (Intelli-
Plate 96-3 Low Profile, Art Robbins Instruments, USA) at 4 °C. Prior to crystallization, hSirt256-
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356 (20 mg mL
-1) was incubated with 14d (100 mM stock solution in DMSO, 1% (v/v) final 
DMSO concentration) and NAD+ (100 mM stock solution in 25 mM Tris/HCl, 150 mM NaCl, 
pH 8.0, final concentration 10 mM, Sigma-Aldrich, Germany). Crystals of the hSirt2-14d-
complex were obtained after 2 days in a solution containing 27% (w/v) PEG 3350 in 0.05 M 
HEPES buffer at pH 7.0 with a protein solution to reservoir ratio of 3:1. The crystal was 
mounted on a nylon loop and cryoprotected by the addition of 20% (v/v) glycerol. 
5. Cell Culture: HeLa (ATCC-2) cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(high glucose) supplemented with 10% (v/v) fetal calf serum, 100 µg/ml kanamycin (all reagents 
from Sigma-Aldrich) in a humidified incubator at 37 °C with 5% CO2. For microscopic analysis, 
0.5 x 104 cells were seeded on 12 mm diameter coverslips placed in 24-well plates and incubated 
overnight before the experiment. For immunoblotting, 1.5 x 104 cells were seeded per well of 24-
well plates and incubated overnight. The drugs were added to cells for 1 hour from 10 mM stock 
solutions in DMSO. Controls contained the corresponding amount of vehicle (DMSO). 
6. Immunoblotting: For the detection of acetylated tubulin, total tubulin and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) levels in cellular samples, we kept the cells at 37 °C and 
washed them with prewarmed PBS. Next, the cells were lysed in 100 µL 1x reducing sample 
buffer containing protein inhibitor mix and 2 mM EDTA (Sigma-Aldrich). Samples were 
centrifuged at 10,000 g at 4°C for 5 min and the supernatants were stored at -70 °C. Samples 
were analyzed by SDS-PAGE and blotted onto polyvinylidene difluoride membrane (Millipore). 
The blot was developed sequentally using a monoclonal mouse antibody against acetylated 
alpha-tubulin at Lys-40 (1:5000, clone 6-11B-1), than using a monoclonal mouse antibody 
against alpha-tubulin (1:5000, clone DM1A), next using a monoclonal mouse antibody against 
GAPDH (1 µg/mL, CB1001, clone 6C5, Calbiochem). Antibodies were detected by anti-mouse 
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IgG-peroxidase conjugate (Fc-specific), (1:5000, Sigma-Aldrich). Peroxidase reaction detected 
using Immobilon Western substrate (Millipore) by a Bio-Rad ChemiDoc MP Imaging system 
and its ImageLab 4.1 software. Intensity of spots was analysed by ImageJ 1.49 using Measure 
command and subtracting background values. The sample values were normalized by the 
average control value on the corresponding blot. 
7. Immunofluorescence microscopy: Immunofluorescence microscopy was performed as 
previously reported.30 
8. Computational Methods: 3D structures of all compounds in this study were generated from 
SMILES strings, and a subsequent energy minimization was carried out using the MMFF94x 
force field implemented in Molecular Operating Environment System (MOE) 2012.10 
(Chemical Computing Group, Montreal, Canada). All compounds were used in the protonation 
state at physiological level. A maximum of 100 conformations were generated for each ligand 
using the Conformational Search module implemented in MOE. All protein structures were 
prepared by using the Structure Preparation module in MOE. Hydrogen atoms were added and 
the protonation state for titratable amino acids was calculated using the Protonate 3D module in 
MOE. Protein structures were energy minimized using the AMBER99 force field53 with a 
tethering force constant of (3/2) kT / 2 (σ = 0.5 Å) for all atoms during the minimization. AM1-
BCC charges were used for ligands.54 All molecules except the zinc ion were removed from the 
structures. Protein-ligand docking was performed using program GLIDE (Suite 2012-5.8, 
Schrödinger LLC, New York, USA). The position of the inhibitor 10 in its crystal structure with 
hSirt2/Ac-Lys-H3 peptide (PDB ID 4RMH) was used to define the size of the grid box (10 Å 
radius). Docking was performed using GLIDE-Extra Precision (XP). The ligand was treated as 
flexible and 20 docking poses were calculated for each inhibitor. All other options were left at 
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their default values. The top-ranked pose from each docking run was included in the final 
analysis and viewed graphically together with the protein structure using the program MOE 
2010.13 (Chemical Computing Group, Montreal, Canada). Using the docking setup, 10 could be 
correctly docked into its crystal structure with RMSD values below 0.5 Å (PDB ID 4RMG and 
4RMH).30 Also, other active aminothiazole derivatives were predicted to adopt a similar binding 
mode as was observed for 10. Binding free energies for the inhibitors in this study were 
calculated using the top-ranked docking poses. Structurally conserved water molecules included 
for docking studies were maintained during the geometry optimization of the complexes. The 
protein-inhibitor complexes were energy minimized using the AMBER PFROSST force field and 
the GBSA solvation model implemented in MOE 2012.10. Using the resulting ∆EGBSA value as 
descriptor, a significant correlation to the pIC50 values was observed (r
2=0.67, RMSE=0.60) for 
the 30 compounds for which an IC50 and exact stereochemistry was determined (Figure S1). 
Besides the correlation coefficient r2, the model was also tested using leave one out (LOO) cross-
validation (q2LOO=0.62). Furthermore, we investigated the effect of other descriptors like ligand 
charge, diameter, or polar surface descriptors for establishing a QSAR model. We successfully 
applied this approach recently for establishing predictive models with high robustness.55 Among 
192 tested 2D descriptors in MOE, the “diameter” and the topological surface descriptor 
“PEOE_VSA+4” showed the highest correlation. A QSAR model based on three descriptors, 
namely “∆EGBSA score”, “diameter”, and “PEO_VSA+4” using MOE PLS methodology was 
generated and validated. The final PLS model yielded a correlation coefficient of r2=0.81 
(RMSE=0.45) and a q2LOO of 0.76 demonstrating the robustness of the model (Figure S2, Table 
S1). Since LOO cross-validation is sometimes misleading and resulting in too optimistic models, 
a more demanding cross-validation procedure was applied for the QSAR model. 10-fold cross 
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validation was carried out using randomly selected compounds (20%) as test set. Repeating this 
random splitting 10 times, resulted in a mean q2 L20%O value of 0.74, demonstrating the 
robustness of the model. All results are summarized in Table S2 in the Supplementary 
Information. 
9. Chemistry: Starting materials and reagents were obtained from commercial suppliers and 
used without further purification. Thin-layer chromatography (TLC) for reaction monitoring was 
performed with alumina plates coated with Merck silica gel 60 F254 (layer thickness: 0.2 mm) 
and analyzed under UV-light (254 nm). A mixture of ethyl acetate and cyclohexane (2:1) was 
used as mobile phase. If the purity of the synthesized compounds was not adequate, we 
performed flash column chromatography with TELOS Flash-LL Silica Columns 60M (0.040-
0.063 mm, 230-400 mesh) as a stationary phase on a Biotage Isolera One automated flash 
purification system with UV-Vis detector. Cyclohexane and ethyl acetate was used as mobile 
phase and gradient was adjusted based on TLC results. Yields were not optimized. 1H-NMR and 
13C-NMR spectra were recorded on Bruker Avance III HD spectrometer at 400 MHz and 100 
MHz. The spectra are referenced against the NMR solvents and are reported as follows: 1H: 
chemical shift δ (ppm), multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, 
q = quartet, quint = quintet, sex = sextet, m = multiplet, b = broad), integration, coupling 
constant (J in Hz). 13C: chemical shift δ (ppm), abbreviations: (q) = quaternary carbons, 
quaternary carbons that could not be found in 13C spectra but in HMBC or HSQC are 
additionally marked with an asterisk (*). The assignment resulted from HMBC and HSQC 
experiments. Purity was determined for all tested compounds by HPLC and UV detection (λ = 
210 nm) and was > 95%. HPLC analysis was performed using the following conditions: Eluent 
A: H2O containing 0.05% TFA, Eluent B: acetonitrile containing 0.05% TFA, Eluent C: n-
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hexane, Eluent D: propan-2-ol, flow rate 1 mL min-1. Method 1.1 (M1.1), analytical column, 
Phenomenex SynergiTM 4 µm MAX-RP 80 Å, 150 x 4.6 mm, isocratic conditions (A = 55%, B = 
45%). Method 1.2 (M1.2), analytical column, Phenomenex SynergiTM 4 µm HYDRO-RP 80 Å, 
250 x 4.6 mm. Method 1.3 (M1.3), analytical column, Phenomenex SynergiTM 4 µm POLAR-RP 
80 Å, 150 x 4.6 mm. Method 2.1 (M2.1), analytical column, Phenomenex SynergiTM 4 µm 
MAX-RP 80 Å, 150 x 4.6 mm, isocratic conditions (A = 40%, B = 60%). Method 2.2 (M2.2), 
analytical column, Phenomenex SynergiTM 4 µm POLAR-RP 80 Å, 150 x 4.6 mm. Method 3 
(M3), analytical column, Phenomenex SynergiTM 4 µm HYDRO-RP 80 Å, 250 x 4.6 mm, 
isocratic conditions (A = 30%, B = 70%). Method 4 (M4), analytical column, Phenomenex 
SynergiTM 4 µm HYDRO-RP 80 Å, 250 x 4.6 mm, isocratic conditions (A = 65%, B = 35%). 
Method 5 (M5), analytical column, Phenomenex SynergiTM 4 µm HYDRO-RP 80 Å, 250 x 4.6 
mm, isocratic conditions (A = 5%, B = 95%). Method 6.1 (M6.1), analytical column, 
Phenomenex SynergiTM 4 µm HYDRO-RP 80 Å, 250 x 4.6 mm, linear gradient conditions (0−4 
min, A = 90%, B = 10%; 4−29 min, linear increase to 100 % of B; 29−31 min, B = 100%; 31−40 
min, A = 10%, B = 90%). Method 6.2 (M6.2), analytical column, Phenomenex SynergiTM 4 µm 
MAX-RP 80 Å, 150 x 4.6 mm. Method 6.3 (M6.3), analytical column, Phenomenex SynergiTM 
4 µm HYDRO-RP 80 Å, 250 x 4.6 mm. Method 7 (M7), analytical column, Phenomenex LuxTM 
5 µm CELLULOSE-1, 250 x 4.6 mm, linear gradient conditions (0−4 min, C = 90%, D = 10%; 
4−30 min, linear increase to C = 50%, D = 50%; 30−36 min, linear gradient to C=90%, D=10%, 
36–40 min C=90%, D=10%. Melting temperatures were determined in glass capillary tubes with 
the Stuart Melting Point Apparatus SMP2. Optical rotation was measured with a PerkinElmer 
Model 341 Polarimeter. Mass spectra with electrospray ionization (ESI) were recorded on an 
Advion expression CMS spectrometer, with electron ionization (EI) on an Agilent Technologies 
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6890 N Network GC-MS system. The synthesis of compounds 16e,35a 22b,36 23b,37 33,56 has 
already been reported. Due to changes in the experimental procedure and to show unpublished 
characterization data, we have outlined the synthesis and the characterization data for those 
compound as well. 
General Procedure for the Synthesis of 1,3,4-Thiadiazol-2-amines (11a-e):31 A well-stirred 
mixture of thiosemicarbazide (1 equiv, 25 mmol), the carboxylic acid (1.2 equiv), and 8 mL of 
concentrated sulphuric acid was slowly heated to 80 – 90 °C and maintained at this temperature 
for 7 hours. After cooling, the reaction mixture was poured into ice water and was treated with 
concentrated ammonia to pH = 12. The crude product, which precipitated upon the addition of 
the ammonia, was filtered off and washed with water. 
5-(1-Naphthylmethyl)-1,3,4-thiadiazol-2-amine (11b):57 From thiosemicarbazide and 1-
naphthylacetic acid. Yield: 3% of a beige solid. Rf : 0.15; 
1H-NMR (DMSO-D6, δ [ppm]): 
8.16-8.09 (m, 1H, naphthyl H-8), 7.98-7.92 (m, 1H, naphthyl H-5), 7.90-7.82 (m, 1H, naphthyl 
H-4), 7.60-7.43 (m, 4H, naphthyl H-2,3,6,7), 6.97 (bs, 2H, -NH2), 4.62 (s, 2H, Ar-CH2-Ar); 
13C-NMR (DMSO-D6, δ [ppm]): 169.01 q (aminothiadiazole C-2), 158.20 q (aminothiadiazole 
C-5), 134.54 q (naphthyl C-1), 133.93 q (naphthyl C-4a), 131.66 q (naphthyl C-8a), 128.99 
(naphthyl C-5), 128.18 (naphthyl C-4), 127.53 (naphthyl C-2), 126.74 (naphthyl C-7), 126.32 
(naphthyl C-6), 126.11 (naphthyl C-3), 124.30 (naphthyl C-8), 33.80 (Ar-CH2-Ar); ESI-MS(+): 
242.1 [M+H]+ 
General Procedure for Acylation of Thiazol-2-amines and 1,3,4-Thiadiazol-2-amines to 
generate amides (12a-g, 17a-j, 18a-i, 24a-b, 31, 37, 43, 44):32 To a solution of the amine 
(1 equiv, 2 mmol), dissolved in 10-30 mL acetonitrile, N,N-diisopropylethylamine (1.5 equiv) 
was added. The mixture was stirred and cooled to 0 °C. The acyl chloride (1.5 equiv) was 
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gradually added with stirring and cooling. After stirring for 2 h at room temperature, volatiles 
were evaporated. The red brown, oily residue was mixed with water (10-30 mL) and precipitates 
were collected by filtration. Precipitates were washed with water, hydrochloric acid (1 M), water, 
and dried to yield the corresponding amide.  
2-Chloro-N-[5-[(7-chloro-1-naphthyl)methyl]thiazol-2-yl]acetamide (17f): From 15d and 
2-chloroacetyl chloride. Yield: 98% of a beige solid; Rf : 0.75; 
1H-NMR (DMSO-D6, δ [ppm]): 
12.32 (bs, 1H, amide-NH), 8.19 (d, 1H, 4J = 2.07 Hz, naphthyl H-8), 8.01 (d, 1H, 3J = 8.85 Hz, 
naphthyl H-5), 7.91-7.88 (m, 1H, naphthyl H-4), 7.56-7.49 (m, 3H, naphthyl H-2,3,6), 7.34-7.32 
(m, 1H, aminothiazole H-4), 4.59 (s, 2H, Ar-CH2-Ar), 4.32 (s, 2H, -CH2-Cl); 
13C-NMR 
(DMSO-D6, δ [ppm]): 165.13 q (amide-C), 156.67 q (aminothiazole C-2), 136.02 q (naphthyl 
C-1), 135.38 (aminothiazole C-4), 132.35 (naphthyl-C4a), 132.22 q (naphthyl C-8a), 132.00 q 
(aminothiazole C-5), 131.45 q (naphthyl C-7), 131.29 (naphthyl C-5), 128.26 (naphthyl C-2), 
127.79 (naphthyl C-4), 126.81 (naphthyl C-3), 126.70 (naphthyl C-6), 123.24 (naphthyl C-8), 
42.62 (-CH2-Cl), 29.60 (Ar-CH2-Ar); ESI-MS(-): 349.0 [M-H]
- 
General Procedure for S-Alkylation to generate Thioethers (13a-h, 14a-k, 14m-o, 14q-r, 
19a-e, 19g-q, 20a, 20c-d, 26a-b, 28-30, 32)32 The aromatic thiol (1 equiv, 0.5 mmol) was 
dissolved in 2 mL of DMSO. Na2CO3 (2 equiv) and KI (1 equiv) were added. The mixture was 
stirred for 15 min at room temperature. Then, the alkyl chloride (1 equiv) was added to the 
reaction mixture and stirred for 2 h. After completion, water (10 mL) was added. The aqueous 
layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over 
Na2SO4 and evaporated. If necessary, the product was purified by automated flash column 
chromatography (cyclohexane/EtOAc: gradient). 
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N-[5-[(7-Chloro-1-naphthyl)methyl]thiazol-2-yl]-2-(4,6-dimethylpyrimidin-2-yl)sulfanyl-
acetamide (14a): From 17f and 33. Yield: 66% of a beige solid; mp: 217-219 °C; Rf : 0.62; 
1H-NMR (DMSO-D6, δ [ppm]): 12.20 (bs, 1H, amide-NH), 8.17 (d, 1H, 
4J = 2.12 Hz, naphthyl 
H-8), 8.00 (d, 1H, 3J = 8.62 Hz, naphthyl H-5), 7.88 (dd, 1H, 3J = 7.12 Hz, 4J = 2.25 Hz, naphthyl 
H-4), 7.55-7.47 (m, 3H, naphthyl H-2,3,6), 7.30-7.28 (m, 1H, aminothiazole H-4), 6.93 (s, 1H, 
pyrimidine H-5), 4.56 (s, 2H, Ar-CH2-Ar), 4.05 (s, 2H, -CH2-S-Ar), 2.26 (s, 6H, 
pyrimidine -CH3); 
13C-NMR (DMSO-D6, δ [ppm]): 169.28 q (pyrimidine C-2), 167.38 q 
(pyrimidine C-4,6), 167.24 q (amide-C), 157.09 q (aminothiazole C-2), 136.08 q (naphthyl C-1), 
135.32 (aminothiazole C-4), 132.34 q (naphthyl C-4a), 132.23 q (naphthyl C-8a), 131.41 q 
(aminothiazole C-5), 131.35 q (naphthyl C-7), 131.27 (naphthyl C-2), 128.23 (naphthyl C-5), 
127.74 (naphthyl C-4), 126.77 (naphthyl C-6), 126.66 (naphthyl C-3), 123.24 (naphthyl C-8), 
116.50 (pyrimidine C-5), 34.43 (-CH2-S-Ar), 29.64 (Ar-CH2-Ar), 23.61 (pyrimidine -CH3); 
Purity: 99.3% (11.28 min, M2.2); ESI-MS(+): 477.1 [M+Na]+ 
General Procedure for the Synthesis of 5-(Arylmethyl)thiazol-2-amines (15a-f, 16g):35 The 
aromatic amine (1 equiv, 20 mmol) was dissolved in a minimal amount of aqueous hydrochloric 
acid (2 M) under heating. The mixture was vigorously stirred and cooled to -5 – 0 °C. The 
hydrochloride partially precipitates. Then, a cooled and acidified solution of NaNO2 (2.5 M, 1 
equiv) was added dropwise. The reaction mixture was stirred for 10 min at -5 – 0 °C. FeCl3 x 6 
H2O (3 equiv) was dissolved in a minimal amount of H2O and added to the generated yellow 
colored arenediazonium chloride solution. Concentrated hydrochloric acid was given to the 
stirred reaction mixture until arenediazonium tetrachloroferrate(II) precipitated quantitatively. 
The temperature was maintained at -5 – 0 °C. The precipitated salt was filtered off and dried. A 
solution of CuCl2 x 2 H2O (0.5 equiv) in 23 mL of ethanol and 1.5 mL of concentrated 
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hydrochloric acid was added at -5 - 0 °C to a solution of the arenediazonium 
tetrachloroferrate(II) (1 equiv) in 30 mL of acetone. The precipitate of arenediazonium 
tetrachlorocuprate(II) was filtered off, washed with diethyl ether, and dried under reduced 
pressure. An additional amount of the salt was precipitated from the filtrate by adding 50 mL of 
diethyl ether. The arenediazonium tetrachlorocuprate(II) was gradually added in portions to 
acrolein (2.5 equiv) dissolved in 40 mL of aqueous acetone (1:1 (v/v)) while stirring at room 
temperature. After the evolution of nitrogen has stopped, water (50 mL) was added. Diethyl ether 
was added to extract the α-chloropropanal from the aqueous layer. Combined organic layers 
were dried over Na2SO4 and solvents were evaporated. The crude α-chloropropanal (1 equiv) 
was dissolved in ethanol (20 mL), and thiourea (1.6 g, 21 mmol) was added. The reaction 
mixture was heated under reflux for 2 h. After cooling to room temperature, water (100 mL) was 
added and the mixture was neutralized with ammonia. The aqueous layer was extracted with 
ethyl acetate (3 x 100 mL). The combined organic layers were dried over Na2SO4 and volatiles 
were evaporated. The brown crude product was purified by automated flash column 
chromatography (cyclohexane/EtOAc: gradient) to yield the aminothiazole. 
5-[(7-Chloro-1-naphthyl)methyl]thiazol-2-amine (15d): From 21b. Yield: 25% of a beige 
solid; Rf : 0.27; 
1H-NMR (DMSO-D6, δ [ppm]): 8.16 (d, 1H, 
4J = 2.00 Hz, naphthyl H-8), 7.99 
(d, 1H, 3J = 8.81 Hz, naphthyl H-5), 7.88-7.84 (m, 1H, naphthyl H-4), 7.53 (dd, 1H, 3J = 8.81 Hz, 
4J = 2.00 Hz, naphthyl H-6), 7.51-7.45 (m, 2H, naphthyl H-2,3), 6.75-6.72 (m, 1H, aminothiazole 
H-4), 6.69 (bs, 2H, -NH2), 4.37 (s, 2H, -CH2-); 
13C-NMR (DMSO-D6, δ [ppm]): 168.14 q 
(aminothiazole C-2), 136.46 q (naphthyl C-1), 136.07 (aminothiazole C-4), 132.30 q (naphthyl 
C-8a), 132.28 q (naphthyl C-4a), 131.26 q (naphthyl C-7), 131.21 (naphthyl C-5), 127.92 
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(naphthyl C-2), 127.51 (naphthyl C-3), 126.69 (naphthyl C-6), 126.64 (naphthyl C-4), 124.63 q 
(aminothiazole C-5), 123.28 (naphthyl C-8), 30.16 (-CH2-); ESI-MS(+): 275.1 [M+H]
+ 
General Procedure for the Synthesis of 5-(Arylmethyl)thiazol-2-amines (16a-f):35a The aniline 
derivative (1 equiv, 20 mmol) was dissolved in a minimal amount of aqueous hydrochloric acid 
(2 M) under heating. The mixture was vigorously stirred and cooled to -5 – 0 °C. The 
hydrochloride partially precipitates. Then, a cooled and acidic solution of NaNO2 (2.5 M, 1 
equiv) was added dropwise to the reaction mixture. The reaction mixture was incubated for 10 
min at -5 – 0 °C. In the synthesis of 16b-e the generated yellow colored arenediazonium chloride 
solution was preliminary neutralized with NaHCO3 to a pH of 6-7, and MgO (0.25 equiv) was 
added to the mixture. The acidic (16a, 16f) or neutralized (16b-e) solution of the arenediazonium 
chloride was added dropwise to a flask, which was loaded with acrolein (1 equiv), CuCl2 x 2 
H2O (0.3 equiv), and 5 mL of acetone. The reaction mixture was stirred at room temperature 
until the evolution of nitrogen stopped. Then, the organic layer was separated, and the aqueous 
layer was extracted with diethyl ether. The organic layer was combined with the extracts, dried 
over Na2SO4, and solvents were removed under reduced pressure. The crude α-chloropropanal 
(1 equiv) was dissolved in ethanol (20 mL) and thiourea (1.6 g, 21 mmol) was added. The 
reaction mixture was heated under reflux for 2 h. After cooling to room temperature, water 
(100 mL) was added and the mixture was neutralized with ammonia. The aqueous layer was 
extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over Na2SO4 
and volatiles were evaporated. The brown crude product was purified by automated flash column 
chromatography (cyclohexane/EtOAc: gradient) to yield the aminothiazole. 
5-(m-Tolylmethyl)thiazol-2-amine (16e): From 3-methylaniline as previously reported.35a 
Yield: 3% of a beige solid; Rf : 0.28; 
1H-NMR (CDCl3, δ [ppm]): 7.25-7.19 (m, 1H, 3-tolyl H-5), 
Page 33 of 47
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 34
7.10-7.02 (m, 3H, 3-tolyl H-2,4,6), 6.82-6.78 (m, 1H, aminothiazole H-4), 5.31 (bs, 2H, -NH2), 
3.93 (s, 2H, Ar-CH2-Ar), 2.36 (s, 3H, 3-tolyl -CH3); 
13C-NMR (CDCl3, δ [ppm]): 167.83 q 
(aminothiazole C-2), 139.71 q (3-tolyl C-1), 138.19 q (3-tolyl C-3), 135.31 (aminothiazole C-4), 
129.10 (3-tolyl C-2), 128.43 (3-tolyl C-5), 127.76 q (aminothiazole C-5), 127.35 (3-tolyl C-4), 
125.35 (3-tolyl C-6), 33.24 (Ar-CH2-Ar), 21.37 (3-tolyl -CH3); ESI-MS(+): 205.1 [M+H]
+ 
General Procedure for the Reduction of Nitronaphthalenes to generate Naphthalenamines 
(21a-c): The nitronaphthalene (1 equiv, 12 mmol) and SnCl2 x 2 H2O were suspended in 100 mL 
of ethanol. The reaction mixture was stirred for 4 - 24 h at room temperature. After completion, 
the solvent was evaporated, and residues were suspended in 1 L of NaOH (1 M). The product 
was extracted with ethyl acetate (3 x 200 mL). Combined organic layers were dried over Na2SO4 
and evaporated under reduced pressure. The crude product was purified by automated flash 
column chromatography (cyclohexane/EtOAc: gradient).  
7-Chloronaphthalen-1-amine (21b): From 23b. Yield: 65% of a purple solid; Rf : 0.90; 
1H-NMR (CDCl3, δ [ppm]): 7.84 (d, 1H, 
4J = 1.93 Hz, H-8), 7.76 (d, 1H, 3J = 8.87 Hz, H-5), 7.42 
(dd, 1H, 3J = 8.87 Hz, 4J = 1.93 Hz, H-6), 7.32-7.29 (m, 2H, H-3,4), 6.85-6.82 (m, 1H, H-2), 4.17 
(bs, 2H, -NH2); 
13C-NMR (CDCl3, δ [ppm]): 141.25 q (C-1), 132.55 q (C-4a), 130.63 q (C-7), 
130.09 (C-5), 126.63 (C-6), 126.57 (C-3), 124.31 q (C-8a), 120.20 (C-8), 118.83 (C-4), 110.76 
(C-2); ESI-MS(-): 176.1 [M-H]- 
Synthesis of Nitronaphthalenamines (22a-b):36 Concentrated sulfuric acid (120 mL) was 
cooled to -5 to -10 °C and treated slowly with 2-aminonaphthalene-1-sulfonic acid (1 equiv, 70.5 
mmol) under vigorous stirring. Most of the 2-aminonaphthalene-1-sulfonic acid was soluble and 
the liquid was cooled to -15 °C. Dry powdered potassium nitrate (1 equiv) was added. The 
brown solution was stirred for 40 min at this temperature and then poured onto 0.5 kg of ice. The 
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precipitate was filtered off, washed, and then extracted with a cold diluted sodium carbonate 
solution. The filtered extracts were cooled to 5 °C and acidified with concentrated hydrochloric 
acid. After 2 h on ice, a mixture of mono-nitrated 2-aminonaphthalene-1-sulfonic acids was 
filtered off, washed with ice water, and dried. The reaction yielded 9.65g (95%) of a tan 
crystalline powder. Without further purification, the mixture of mono-nitrated 
2-aminonaphthalene-1-sulfonic acids was suspended in 140 mL of 45% sulfuric acid and 
refluxed for 40 min. The hot mixture was diluted to 2 L with water and an aqueous solution of 
sodium hydroxide was added to a basic pH. The suspension was cooled to 10 °C for 1.5 h, and 
the precipitated material was filtered off, washed with water, and dried. The structural isomers 
were separated by automated flash column chromatography (cyclohexane/EtOAc: gradient).  
8-Nitronaphthalen-2-amine (22b): Yield: 27% of a deep red solid; Rf : 0.86; 
1H-NMR 
(DMSO-D6, δ [ppm]): 8.18 (dd, 1H, 
3J = 7.84 Hz, 4J = 1.26 Hz, naphthyl H-7), 8.06-8.00 (m, 1H, 
naphthyl H-5), 7.80 (d, 1H, 3J = 8.87 Hz, naphthyl H-4), 7.54 (d, 1H, 4J = 2.29 Hz, naphthyl 
H-1), 7.18 (t, 1H, 3J = 7.84 Hz, naphthyl H-6), 7.08 (dd, 1H, 3J = 8.87 Hz, 4J = 2.29 Hz, naphthyl 
H-3), 6.19 (s, 2H, -NH2); 
13C-NMR (DMSO-D6, δ [ppm]): 151.33 q (naphthyl C-2), 143.12 q 
(naphthyl C-8), 135.64 (naphthyl C-5), 130.84 (naphthyl C-4), 128.12 q (naphthyl C-4a), 127.75 
q (naphthyl C-8a), 125.70 (naphthyl C-7), 119.65 (naphthyl C-3), 118.95 (naphthyl C-6), 101.12 
(naphthyl C-1); ESI-MS(-): 187.1 [M-H]-.  
General Procedure for the Synthesis of Halonitronaphthalenes (23a-c):37 The respective 
nitronaphthylamine (1 equiv, 32.6 mmol) was dissolved in 33 mL of glacial acid. A solution of 
sodium nitrite (1.7 equiv) dissolved in 33 mL of concentrated sulfuric acid was added gradually 
with stirring, the temperature was kept at 15-20 °C. After another 15 min, the arenediazonium 
salt solution was added dropwise while stirring to a solution of freshly prepared cuprous(I) 
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halogenide (4 equiv) dissolved in 50 mL of concentrated hydrochloric acid (for 23a-b), or 
hydrobromic acid (for 23c). After the termination of nitrogen evolution, water was added to the 
reaction mixture to precipitate the product quantitatively. Precipitates were filtered off, washed 
with aqueous NaOH (2 M) and water.  
7-Chloro-1-nitro-naphthalene (23b): From 22b and CuCl dissolved in concentrated 
hydrochloric acid. Yield: 58% of a pale yellow solid; Rf : 0.88; 
1H-NMR (CDCl3, δ [ppm]): 8.69 
(d, 1H, 4J = 1.95 Hz, H-8), 8.34 (dd, 1H, 3J = 7.80 Hz, 4J = 1.18 Hz, H-2), 8.16-8.11 (m, 1H, H-
4), 7.93 (d, 1H, 3J = 8.79 Hz, H-5), 7.60 (dd, 1H, 3J = 8.79 Hz, 4J = 1.95 Hz, H-6), 7.59 (t, 1H, 3J 
= 7.80 Hz, H-3); 13C-NMR (CDCl3, δ [ppm]): 145.39 q (C-1), 136.12 q (C-7), 134.67 (C-4), 
132.55 q (C-4a), 130.08 (C-5), 128.49 (C-6), 125.74 q (C-8a), 125.27 (C-2), 124.43 (C-3), 
122.52 (C-8); EI-MS(-): 207 [M]- 
2-Mercapto-4,6-dimethylpyrimidine (33)56 as an Example for the General Procedure for the 
Synthesis of 2-Mercaptopyrimidines: Thiourea (1 equiv, 26 mmol) and acetylacetone (1.5 equiv) 
were dissolved in ethanol. During cooling and stirring, 2.5 mL of concentrated sulfuric acid were 
added to the flask. After 48 h of stirring at room temperature, the reaction mixture was heated to 
a slight boiling under reflux for 30 min. After cooling to room temperature, the yellow 
crystalline mass was filtered off, washed with ice-cold ethanol, and dried under reduced pressure. 
The yellow solid was solved in a minimal amount of water. Barium carbonate was added to a 
neutral reaction. The clear filtrate from the barium salts was then evaporated to dryness. The 
crude product was recrystallized from ethanol. Yield: 39% of a yellow solid; Rf : 0.08; 
1H-NMR 
(DMSO-D6, δ [ppm]): 13.40 (bs, 1H, -SH), 6.62 (s, 1H, 5-H), 2,25 (s, 6H, -CH3); 
13C-NMR 
(DMSO-D6, δ [ppm]): 181.67 q (C-2), 164.58 q (C-4,6); 110.16 (C-5); 21,71 (-CH3); ESI-MS(+): 
141.1 [M+H]+  
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